All In Biotech

Drug Trial Radar · NCT07721012

Huanghou Zhixie Diwan in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Exploratory Clinical Study on the Efficacy and Safety of Huanghou Zhixie Diwan in the Treatment of Irritable Bowel Syndrome With Diarrhea (Large Intestinal Damp-heat)

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jul 31, 2026

Primary completion

Aug 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Lei Yunshang GroupIndustry
Sponsor type
Industry
First posted
Jul 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase II clinical trial. Its purpose is to evaluate the efficacy and safety of Huanghou Zhixie Diwan in subjects with irritable bowel syndrome with diarrhea (Large Intestinal Damp-heat syndrome) after 4 weeks of treatment.

Conditions

  • Patients With Irritable Bowel Syndrome With Diarrhea

Interventions

  • Huanghou Zhixie Diwan groupDrug

    The prescription consists of Magnolia Officinalis extract, Coptis Chinensis extract, Zingiber Officinale oil, and Costus Root oil

  • Huanghou Zhixie Diwan mimicDrug

    Placebo with "no pharmaceutically active ingredients", identical to the Huanghou Zhixie Diwan in color, odor and appearance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effective rate of IBS-D (weekly response)Time frame: After 4-week treatment

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Traditional Chinese Medicine Hospital, Capital Medical University

    Beijing, China

  • The First Hospital of Hunan University of Chinese Medicine

    Changsha, China

  • Daqing People's Hospital

    Daqing, China

  • GuangDong Second Traditional Chinese Medicine Hospital

    Guangzhou, China

  • Inner Mongolia Hospital of Traditional Chinese Medicine

    Hohhot, China

  • Lianyungang Hospital of Traditional Chinese Medicine

    Lianyungang, China

  • Luoyang First People's Hospital

    Luoyang, China

  • Luoyang Third People's Hospital

    Luoyang, China

  • Meihekou Central Hospital

    Meihekou, China

  • The Third Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

    Shenyang, China

  • Hebei Provincial Hospital of Traditional Chinese Medicine

    Shijiazhuang, China

  • The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

    Tianjin, China

  • Wenzhou TCM Hospital of Zhejiang Chinese Medical University

    Wenzhou, China

  • Xiamen Hospital of Traditional Chinese Medicine

    Xiamen, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.